Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 6, 1996

View Archived Issues

New analgesic compounds with novel mechanism of action disclosed by Novo Nordisk

Anti-E-selectin antisense compound from Isis inhibits mRNA splicing

ChemGenics/Wyeth-Ayerst antibacterial drug discovery collaboration

Cytovene approved for new indication in U.S.

Connective Therapeutics acquires rheumatoid arthritis Rx from SKB

PAI-1 diagnostic approved for marketing in U.S.

Successful pivotal Mexican trial for oral impotency therapy

Varian, University of Arizona collaborate on methods of enhancing gene therapy efficacy

FDA tentatively approves generic NSAID

SKB, IDEC initiate phase III testing of antirheumatic antibody

Oncogene Science issued patent on gene transcription

Cytel to implement new development strategy for HBV vaccine

Etex signs marketing agreement for bone substitute

Sepracor gets go-ahead for U.S. clinical trials on (S)-oxybutynin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...